Essential Thrombocythemia Archives - Oncology Nurse Advisor

MPN Genomic Calculator Performs Well in Real-Life Cohort of Patients With Essential Thrombocythemia

By

July 29, 2020

The MPN Genomic Calculator uses clinical, laboratory, and genomic characteristics of patients with MPN to estimate their clinical outcomes.

Woman extracting a pill from the blister

Myeloproliferative Neoplasms

Cutaneous AEs Are Common in Patients With MPNs Treated With Hydroxyurea

By

Susan Moench, PhD, PA-C

July 27, 2020

Previously conducted retrospective studies may have underestimated the incidence of hydroxyurea-related skin toxicity in patients with MPNs.

A recent article is only the latest in a series of studies drawing attention to the importance of di

Myeloproliferative Neoplasms

High-Risk Mutations May Underlie Worse Outcomes in Men With MPN, Study Suggests

By

Susan Moench, PhD, PA-C

July 1, 2020

This study showed that MPN is more aggressive in men vs women and explored whether sex differences in the genomic landscape of MPN could explain this difference.

Platelet aggregation and platelet activation were both independently associated with bleeding risk.

Myeloproliferative Neoplasms

Evaluation of Real-World Experience With Long-Term Use of Anagrelide in the Setting of Essential Thrombocythemia

By

Susan Moench, PhD, PA-C

June 10, 2020

Anagrelide, a platelet-lowering agent with US FDA approval and EMA licensing for the treatment of patients with ET, is associated with prolonged response to initial therapy.

The novel drug appeared effective in healthy, previously untreated patients, but cost, side effects, and other issues may stand in the way of its widespread use.

Myeloproliferative Neoplasms

Acute Hospital Care Drives Healthcare Expenditures in Patients With MPN, Study Finds

By

Susan Moench, PhD, PA-C

May 29, 2020

An additional notable finding from this study was that the absence of specialist care was associated with higher healthcare costs among patients with MPNs.

Myeloproliferative Neoplasms

Low-Dose Aspirin Administered Twice-Daily Is Optimal for Thrombosis Reduction in Essential Thrombocythemia, Study Finds

By

Susan Moench, PhD, PA-C

April 22, 2020

Previous mostly retrospective/observational studies evaluated low-dose aspirin administered once daily in the setting of ET. In this study, the more frequent dosing was found optimal.

Though lymphoproliferative diseases during pregnancy can lead to complications, a host of treatment options exists.

Myeloproliferative Neoplasms

Pregnancy in Myeloproliferative Neoplasms: Aspirin May Raise Likelihood of Live Birth

By

Jonathan Goodman, MPhil

March 16, 2020

Researchers examined pregnancy outcomes in 102 patients with essential thrombocythemia.

An illustration of a thrombosis forming.

Myeloproliferative Neoplasms

Splanchnic Vein Thrombosis at Presentation of Polycythemia Vera or Essential Thrombocythemia Associated With Increased Mortality

By

Susan Moench, PhD, PA-C

March 11, 2020

This study investigated differences in the morbidity and mortality of patients presenting with PV or ET with and without splanchnic vein thrombosis.

Myeloproliferative Neoplasms

Splenomegaly May Be a Negative Prognostic Factor in Essential Thrombocythemia and Polycythemia Vera

By

Susan Moench, PhD, PA-C

January 22, 2020

Currently, splenomegaly is not included as a prognostic factor in major prognostic models of Philadelphia-negative myeloproliferative neoplasms.

Light micrograph of thrombus inside blood vessel

Myeloproliferative Neoplasms

MPN-Directed Therapy Does Not Alter Timing of Clinical Manifestations of Splanchnic Vein Thrombosis

By

Susan Moench, PhD, PA-C

December 2, 2019

A retrospective analysis sought to determine the association between myeloproliferative neoplasms, MPN-directed therapy, and development of splanchnic vein thrombosis.